The News

Cellzome appoints Dr Jane Dancer as VP Business Development

07/01/2008

Boston, 7th January 2008 - Cellzome Inc. is pleased to announce the appointment of Jane Dancer PhD, MBA as VP Business Development effective immediately.

Dr Dancer has until recently been Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) where she was responsible for negotiating in- and out-licensing activity in relation to CAT’s core technology and patents. This included being part of the team that negotiated the major strategic alliance with AstraZeneca that subsequently led to the acquisition of CAT in 2006. Before joining CAT in 2002, she was with Aventis Crop Science as a Global Project Manager (2000-2001), and with AgrEvo UK Ltd (1990-1999), formerly Schering Agrochemicals Ltd, where she rose to become Team Leader responsible for leading multidisciplinary project teams within the research and early development process.

She has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD in Natural Sciences from the University of Cambridge. Tim Edwards, CEO of Cellzome said: “On behalf of the Board, I am delighted to welcome Jane to Cellzome. She has considerable experience in business development, seeking out and negotiating collaborations with some of the largest pharma and biotech companies. This experience will prove invaluable to Cellzome as it enters its next phase of growth and development.”

About Cellzome Inc.
Cellzome is a privately-owned drug discovery company identifying a new generation of kinase targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for screening and profiling of kinases in relevant cells and tissues.
Cellzome’s emerging pipeline includes a small molecule Histamine H4 receptor antagonist, initially for asthma and allergic rhinitis, which is planned to begin clinical studies in 2008. Cellzome is applying its distinctive Kinobeads™ technology to the discovery and development of novel, selective kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, including PI3Kgamma and ZAP70.
The Company has collaborations with Novartis on the discovery of target-lead pairs in a variety of disease areas, and with Johnson & Johnson for the discovery of novel medicines for the treatment of Alzheimer’s disease.
Cellzome’s holding company is domiciled in the US and it employs about 85 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany.

For further information please contact:
Cellzome AG
Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com
Media Contact
Hogarth Partnership
John Olsen/Melanie Toyne-Sewell
Tel: +44 (0) 207 357 9477
mtoyne-sewell@hogarthpr.co.uk